Eczema does not make you immunocompromised. It is not an immune deficiency. Instead, eczema (atopic dermatitis) involves an immune system that is overactive in some ways and underperforming in others, a pattern researchers call immune dysregulation. Your body’s ability to fight off common illnesses like colds and flu remains intact. However, the condition does create specific vulnerabilities in your skin’s defenses, and certain treatments for eczema can temporarily suppress parts of your immune system.
Why Eczema Feels Like an Immune Problem
Eczema is driven by an overactive branch of the immune system, not a weak one. In people with atopic dermatitis, a group of immune cells called Th2 cells ramp up and flood the skin with inflammatory signals. These signals trigger the production of IgE antibodies (the same ones involved in allergies), recruit eosinophils (a type of white blood cell), and activate mast cells. The result is the redness, swelling, and intense itch you feel during a flare.
This overactivity also suppresses the production of filaggrin, a protein your skin needs to maintain a strong, intact barrier. So while one arm of your immune system is working overtime, it’s actually weakening your skin’s first line of defense. That’s why eczema is described as a disease of both barrier dysfunction and immune dysregulation. It’s not that your immune system is too weak. It’s that it’s aimed in the wrong direction.
Why Skin Infections Are More Common
If eczema isn’t an immune deficiency, why do people with it get more skin infections? The answer comes down to local defenses rather than whole-body immunity. The Th2-heavy immune profile in eczema leads to reduced production of natural antimicrobial peptides in the skin, fewer neutrophils (infection-fighting cells) arriving at the skin surface, and defects in the receptors that detect pathogens. Combined with the cracked, dry barrier that characterizes eczema, bacteria like Staphylococcus aureus can colonize the skin much more easily.
This also explains a condition called eczema herpeticum, where the herpes simplex virus spreads rapidly across damaged skin. People who develop eczema herpeticum tend to have even lower interferon levels (a key antiviral signal) and higher IgE, making their skin particularly vulnerable to viral entry and replication. It’s a serious complication, but it reflects a localized immune imbalance in the skin rather than the kind of systemic immune failure seen in truly immunocompromised individuals.
The Difference Between Dysregulation and Deficiency
Being immunocompromised means your immune system is broadly weakened and unable to mount normal responses to infections. This category includes people undergoing chemotherapy, organ transplant recipients on anti-rejection drugs, and individuals with conditions like HIV/AIDS. These people face elevated risks for infections throughout the body, from pneumonia to fungal infections to reactivated viruses.
Eczema doesn’t fit this picture. Your T cells, B cells, and antibody production all function. In fact, your immune system is producing too much of certain responses, not too little. The vulnerability is concentrated in the skin and is driven by the misdirected inflammatory response rather than by a gap in immune capacity. You wouldn’t be classified as immunocompromised for purposes like vaccine eligibility based on eczema alone.
How Eczema Treatments Affect Immunity
This is where the picture gets more complicated. While eczema itself doesn’t suppress your immune system, some of the medications used to treat it can.
Older systemic treatments like cyclosporine and methotrexate are broad immunosuppressants. They dial down the immune system widely, which is why they work for severe eczema but also raise the risk of infections throughout the body. People on these medications are typically treated as immunosuppressed by their doctors, and vaccine schedules may be adjusted accordingly.
Newer biologic therapies like dupilumab work differently. Dupilumab blocks only the specific inflammatory pathway (IL-4 and IL-13 signaling) that drives eczema, leaving the rest of the immune system alone. Clinical evidence shows dupilumab is actually associated with a reduced risk of skin infections, both viral and bacterial, compared to broader immunosuppressants. By calming the misdirected Th2 response and allowing the skin barrier to recover, it may help restore the skin’s natural defenses rather than weaken them.
JAK inhibitors, a newer class of oral medications for eczema, fall somewhere in between. Drugs in this category suppress multiple immune signaling pathways in a dose-dependent manner. Safety data shows they carry real infection risks: herpes zoster (shingles) is the most common infection-related side effect, and signals for more serious events like pneumonia and sepsis have been reported. Because of this broader immune suppression, patients on JAK inhibitors are advised to avoid live vaccines during treatment and may need additional vaccine doses, following guidelines designed for immunocompromised patients.
What This Means for You Day to Day
If you have eczema but are not on systemic immunosuppressive medication, your immune system functions normally for everyday purposes. You can receive all standard vaccines, including live vaccines. You are not at higher risk for respiratory infections, foodborne illness, or other systemic infections compared to the general population. Your increased infection risk is limited to the skin, and the best way to manage it is to keep your skin barrier intact through consistent moisturizing, prompt treatment of flares, and avoiding known triggers.
If you are taking a JAK inhibitor, cyclosporine, or high-dose oral corticosteroids for your eczema, the treatment itself can create a temporary state of immune suppression. In that case, your doctor may recommend adjustments like avoiding live vaccines, getting additional booster doses of certain vaccines, or monitoring for signs of infection more closely. The immunosuppression comes from the medication, not the eczema, and it resolves when treatment stops.
Keeping the skin well-moisturized and managing flares early does more than reduce itch. It limits the breaks in your skin barrier where bacteria and viruses can enter. For most people with eczema, protecting the skin is the single most effective way to reduce the infection risk that the condition creates.